DSGN · XBRL financial data

Design Therapeutics financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DSGN's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	0	0
Research and development	24,778	48,613	57,063	44,350	59,129
General and administrative	11,053	18,980	21,127	18,033	20,338
Total operating expenses	35,831	67,593	78,190	62,383	79,467
Operating income (loss)	(35,831)	(67,593)	(78,190)	(62,383)	(79,467)
Interest income	—	—	11,328	12,795	9,675
Other income (expense)	298	4,285	11,328	—	—
Income tax expense (benefit)	—	—	—	0	0
Net income (loss)	(35,533)	(63,308)	(66,862)	(49,588)	(69,792)
Earnings per share, basic USD per share	(0.77)	(1.14)	(1.19)	(0.88)	(1.22)
Earnings per share, diluted USD per share	(0.77)	(1.14)	(1.19)	(0.88)	(1.22)
Weighted average shares, basic thousands of shares	45,936	55,708	55,985	56,587	57,330
Weighted average shares, diluted thousands of shares	45,936	55,708	55,985	56,587	57,330

Fiscal years (DSGN's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	298,569	26,500	21,200	22,563	16,856
Marketable securities	85,495	303,887	260,598	222,914	202,989
Prepaid and other current assets	1,371	4,732	2,786	2,563	3,939
Total current assets	385,435	335,119	284,584	248,040	223,784
Property and equipment, net	1,508	1,947	1,691	1,410	981
Right-of-use asset	3,614	3,612	2,938	2,216	1,438
Total assets	390,557	341,137	289,643	252,093	226,203
Accounts payable	1,620	3,025	1,940	2,186	2,312
Accrued liabilities	3,663	7,751	7,682	6,276	10,743
Total current liabilities	5,283	10,776	9,622	8,462	13,055
Lease liability, non-current	3,144	3,051	2,334	1,534	645
Total liabilities	8,427	13,827	11,956	9,996	13,700
Accumulated deficit	(47,456)	(110,764)	(177,626)	(227,214)	(297,006)
Total stockholders' equity	382,130	327,310	277,687	242,097	212,503
Total liabilities and equity	390,557	341,137	289,643	252,093	226,203
Common shares outstanding (cover page) thousands of shares	55,700	55,943	56,494	56,763	61,672

Fiscal years (DSGN's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(35,533)	(63,308)	(66,862)	(49,588)	(69,792)
Stock-based compensation	4,689	10,925	13,088	13,072	14,549
Net cash from operating activities	(29,377)	(51,317)	(58,560)	(43,105)	(54,358)
Purchases of property and equipment	1,538	918	256	340	193
Net cash from investing activities	(53,644)	(220,987)	52,536	43,955	22,913
Proceeds from issuing common stock	—	—	—	0	24,847
Net cash from financing activities	379,211	235	724	513	25,738
Net change in cash	296,190	(272,069)	(5,300)	1,363	(5,707)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Design Therapeutics	15,252	not reported	(15,378)*	64.0M	13.2 quarters	Q3 FY26 10-QSep 30, 2026
Alector	75,472	162,866	(24,154)*	148.9M	3.8 quarters	Q3 FY26 10-QSep 30, 2026
Protalix BioTherapeutics	27,420	19,896	(10,400)*	80.6M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Fate Therapeutics	43,942	0	(27,800)	121.6M	5.1 quarters	Q3 FY26 10-QSep 30, 2026
Caribou Biosciences	26,057	1,607	(22,518)*	108.0M	3.9 quarters	Q3 FY26 10-QSep 30, 2026
Protara Therapeutics	17,076	not reported	(15,389)*	59.1M	10.5 quarters	Q2 FY26 10-QJun 30, 2026
TuHURA Biosciences	996	not reported	(8,634)*	63.7M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Enanta Pharmaceuticals	33,419	14,359	(9,972)*	29.1M	21.2 quarters	Q3 FY26 10-QJun 30, 2026
Galectin Therapeutics	13,269	not reported	(2,439)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 6:08 PM ET. The filing on SEC.gov is the record.